Organ-specific liquid biopsy in lung cancer: the emerging role of exhaled breath condensate
Cancer Treatment and Research Communications · 2026 · 49 · 101463
DOI: 10.1016/j.ctarc.2026.101463 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Síle Toland und 5 weiteren Autor:innen. Beteiligte Einrichtung: Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland. Electronic address: si…. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Liquid biopsy has transformed the management of non-small cell lung cancer (NSCLC). However, current plasma-based approaches face inherent limitations in early-stage and low-burden disease, where tumour-derived DNA fractions are frequently below reliable detection thresholds. As lung cancer care shifts toward earlier detection and minimal residual disease assessment, these constraints expose a critical gap in tumour-proximal molecular sampling. This has prompted growing interest in organ-specific liquid biopsy strategies designed to interrogate biological compartments closer to the site of tumour origin. Exhaled breath condensate (EBC), a non-invasive and lung-derived matrix containing airway lining fluid, represents a biologically rational candidate for such an approach. Emerging translational studies demonstrate the feasibility of detecting tumour-associated genomic alterations and nucleic acids within EBC, suggesting potential utility in early detection, molecular profiling, and longitudinal monitoring. However, substantial challenges remain, including pre-analytical standardisation, analytical validation, and prospective clinical evaluation. This narrative review examines the conceptual rationale for lung-specific liquid biopsy, summarises the evolving evidence supporting EBC, and outlines critical and translational steps required to determine whether EBC can become an integral component of lung cancer diagnostics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland. Electronic address: sile.toland@gmail.com.
- Department of Respiratory Medicine, Tallaght Hospital, Dublin, Ireland.
- Royal College of Surgeons in Ireland, Dublin, Ireland.
- Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland.
- Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
Zitieren
APA
Toland, S., Allen, J., Toomey, S., Ryan, D. J., Morgan, R., & Hennessy, B. T. (2026). Organ-specific liquid biopsy in lung cancer: the emerging role of exhaled breath condensate. Cancer Treatment and Research Communications, 49, 101463. https://doi.org/10.1016/j.ctarc.2026.101463
Vancouver
Toland S, Allen J, Toomey S, Ryan DJ, Morgan R, Hennessy BT. Organ-specific liquid biopsy in lung cancer: the emerging role of exhaled breath condensate. Cancer Treatment and Research Communications. 2026;49:101463. doi:10.1016/j.ctarc.2026.101463
BibTeX
@article{Toland2026,
author = {Toland, Síle and Allen, Jack and Toomey, Sinead and Ryan, Daniel J and Morgan, Ross and Hennessy, Bryan T},
title = {Organ-specific liquid biopsy in lung cancer: the emerging role of exhaled breath condensate},
journal = {Cancer Treatment and Research Communications},
year = {2026},
volume = {49},
pages = {101463},
doi = {10.1016/j.ctarc.2026.101463}
}
EUVIMED